| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 04/24/2003 | WO2003033680A2 Kinases and phosphatases |
| 04/24/2003 | WO2003033653A2 Affinity enhancement agents |
| 04/24/2003 | WO2003033535A2 Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans |
| 04/24/2003 | WO2003033528A1 Cyclic peptides as g-protein-coupled receptor antagonists |
| 04/24/2003 | WO2003033527A2 Cyclosporine analogue mixtures and their use as immunomodulating agents |
| 04/24/2003 | WO2003033526A2 Synthesis of cyclosporin analogs |
| 04/24/2003 | WO2003033524A2 Peptidyl ketones as inhibitors of dpiv |
| 04/24/2003 | WO2003033518A1 Steroidal compounds for inhibiting steroid sulphatase |
| 04/24/2003 | WO2003033507A1 Benzylmalonic acid derivatives and proteasome inhibitors contaiing the same |
| 04/24/2003 | WO2003033506A1 Aminoborane acid derivative and proteasome inhibitory drug containing the same |
| 04/24/2003 | WO2003033502A1 Bicyclic oxopyridine and oxopyrimidine derivatives |
| 04/24/2003 | WO2003033496A1 Beta-carbolin derivatives as ptp-inhibitors |
| 04/24/2003 | WO2003033483A1 Biphenylcarboxylic amide derivatives as p38 kinase inhibitors |
| 04/24/2003 | WO2003033482A1 Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors |
| 04/24/2003 | WO2003033466A1 Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same |
| 04/24/2003 | WO2003033457A1 Biphenyl-derivatives as p38-kinase inhibitors |
| 04/24/2003 | WO2003033029A1 Replication competent dual-ad vectors for vaccine and immunotherapy applications |
| 04/24/2003 | WO2003033010A1 Cyclosporin analogs for the treatment of autoimmune diseases |
| 04/24/2003 | WO2003033002A1 Intracellular calcium concentration increase inhibitors |
| 04/24/2003 | WO2003032997A1 Pyrimidine derivatives, pharmaceutical agent containing said compounds, use and method for making same |
| 04/24/2003 | WO2003032993A1 Use of phosphorodiesterase iv inhibitors |
| 04/24/2003 | WO2003032989A1 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors |
| 04/24/2003 | WO2003032987A1 2'-methyl-5'-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 04/24/2003 | WO2003032986A1 2' -methyl-5-(1,3,4-oxadiazol-2-yl)-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 04/24/2003 | WO2003032982A1 Bis-heteroaryl alkanes as therapeutic agents |
| 04/24/2003 | WO2003032981A1 4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes |
| 04/24/2003 | WO2003032980A1 5'-carbamoyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 04/24/2003 | WO2003032978A1 Pharmaceutical compositions comprising mycophenolic acid or mycophenolate salt |
| 04/24/2003 | WO2003032972A1 5’-carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 04/24/2003 | WO2003032971A1 5’-acylamino-1,1’-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 04/24/2003 | WO2003032970A1 5'-carbamoyl-2'-methyl-1,1'-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors |
| 04/24/2003 | WO2003032964A2 Gap junctions and endothelial-derived hyperpolarizing factor (edhf) |
| 04/24/2003 | WO2003032958A1 Use of a copolymer to produce a galenic form containing a peptide or a protein as active agent |
| 04/24/2003 | WO2003032949A1 Novel cyclosporin analog microemulsion preconcentrates |
| 04/24/2003 | WO2003032928A2 Therapeutic composition and use |
| 04/24/2003 | WO2003032918A2 Treatment of infectious disease using interleukin-1 beta converting enzyme (ice)/ced-3 family inhibitors |
| 04/24/2003 | WO2003032910A2 Carbinols for the treatment of neuropathic dysfunction |
| 04/24/2003 | WO2003032898A2 Modified human thymic stromal lymphopoietin |
| 04/24/2003 | WO2003004049A3 Use of polyclonal anti-hiv goat serum as a therapeutic agent |
| 04/24/2003 | WO2002100437A3 Ophthalmic compositions comprising hyaluronic acid |
| 04/24/2003 | WO2002098907A3 Cation conducting gabaa receptors and their use |
| 04/24/2003 | WO2002068406A3 Substituted amine derivatives and their use for the treatment of angiogenesis |
| 04/24/2003 | WO2002064748A8 Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof |
| 04/24/2003 | WO2002057259A3 Pyrazole compounds useful as protein kinase inhibitors |
| 04/24/2003 | WO2002051988A3 Thymic epithelial progenitor cells and uses thereof |
| 04/24/2003 | WO2002050120A3 High affinity antibodies |
| 04/24/2003 | WO2002046383A3 Protein modification and maintenance molecules |
| 04/24/2003 | WO2002045431A3 Genetically engineered herpes virus for the treatment of cardiovascular disease |
| 04/24/2003 | WO2002030980A3 Use of anti-human integrin alpha d antibodies to treat spinal cord injury |
| 04/24/2003 | WO2002026825A3 G-protein coupled receptors |
| 04/24/2003 | WO2002018585A8 Packaging of positive-strand rna virus replicon particles |
| 04/24/2003 | WO2002009751A8 COMPOSITIONS FOR INDUCING SELF-SPECIFIC ANTI-IgE ANTIBODIES AND USES THEREOF |
| 04/24/2003 | US20030078432 Novel benzotriazoles anti-inflammatory compounds |
| 04/24/2003 | US20030078426 Thiazolidine or oxazolidine compounds useful for preventing or therapeutical agents for various diseases such as diabetes and hyperlipemia |
| 04/24/2003 | US20030078419 For therapy of autoimmune diseases mediated by cathepsin S; for inhibiting the progression of tissue transplant rejection |
| 04/24/2003 | US20030078417 For protecting cells from injury due to intrinsic membrane lysis, oxidation and/or invasion by destructive agents; for therapy of phospholipase mediated injury, injury due to oxidation, and inflammation |
| 04/24/2003 | US20030078409 Nucleotide sequences coding polypeptide for use in the treatment of respiratory system, asthmatic and inflammatory bowel diseases |
| 04/24/2003 | US20030078405 47 human secreted proteins |
| 04/24/2003 | US20030078299 Anti-cancer nitro- and thia-fatty acids |
| 04/24/2003 | US20030078282 For therapy of allergic dermatitis and atopy in animals and humans |
| 04/24/2003 | US20030078280 Macroheterocylic compounds useful as kinase inhibitors |
| 04/24/2003 | US20030078275 For therapy of cancer, diabetes and Alzheimer's disease |
| 04/24/2003 | US20030078270 Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI |
| 04/24/2003 | US20030078265 Inhibitors of nitric oxide synthase (nos) |
| 04/24/2003 | US20030078252 Used to treat abnormal cell growth and central nervous system disorders |
| 04/24/2003 | US20030078246 Combinations for the treatment of inflammatory disorders |
| 04/24/2003 | US20030078166 Pyrazole compounds useful as protein kinase inhibitors |
| 04/24/2003 | US20030077826 Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC) |
| 04/24/2003 | US20030077802 Human PRL1 phosphatase |
| 04/24/2003 | US20030077694 Nucleotide sequences coding polypeptide for use in the treatment of inflammatory disorders |
| 04/24/2003 | US20030077638 MID 4460, a human tyrosine phosphatase family member and uses therefor |
| 04/24/2003 | US20030077341 Processes of making North American ginseng fractions, products containing them, and use as immunomodulators |
| 04/24/2003 | US20030077322 Solid dispersion system of pranlukast with improved dissolution and method for preparing the same |
| 04/24/2003 | US20030077313 Anti-stress composition intended for incorporation mainly in nutritional vehicles |
| 04/24/2003 | US20030077301 Topically administering to a localized region affected by the inflammatory dermatosis on a patient skin a formulation containing a active agent,and a permeation enhancing base to enhance the flux of active agent through skin without damage |
| 04/24/2003 | US20030077291 Active enamel matrix substance, such as an amelogenin, a processed amelogenin product, or a metabolite can be used in treating conditions in a mammal which present an imbalance in its native immune resposne to external or internal stimuli |
| 04/24/2003 | US20030077287 Methods to improve immunogenicity of antigens and specificity of antibodies |
| 04/24/2003 | US20030077286 A T cell receptor ligand which substantially inhibits at least one T cell effector response evoked by fully active peptide-MHC(major histocompatibility complex) available to respond T cells |
| 04/24/2003 | US20030077284 Contacting a B cell antigen receptor, pre-B cell receptor, pro-B cell receptor, Ig Fc receptors, and NK receptors, with a regulatory compound, causes dissociation of extracellular ligand binding component from transducer component |
| 04/24/2003 | US20030077280 Monoclonal antibody which specifically recognizes and forms complex with protein located on surface of activated T cells and thereby inhibits T cell activation of B cells |
| 04/24/2003 | US20030077275 Chimeric antibody specific to human CD4 which comprises the variable heavy and light chain sequences of an Old World monkey monoclonal antibody produced against human CD4 and human constant heavy and light domain sequences |
| 04/24/2003 | US20030077273 Methods of treating antibody-mediated pathologies using agents which inhibit CD21 |
| 04/24/2003 | US20030077257 Administering a dosage of alive larva of nematodes; immunogens treating cancer of the first and second stages, and AIDS-infections |
| 04/24/2003 | US20030077249 DNA coding for one or more recombinant chimeric receptors comprising two or more different cytoplasmic signalling polypeptides; drug delivery system for treating cancer |
| 04/24/2003 | US20030077247 Chemokines as adjuvants of immune response |
| 04/24/2003 | US20030077246 TNFr/OPG-like molecules and uses thereof |
| 04/24/2003 | CA2727642A1 Synthesis of cyclosporin analogs |
| 04/24/2003 | CA2494706A1 Chimeric glycosylphosphatidylinositol containing peptides |
| 04/24/2003 | CA2463996A1 Replication competent dual-ad vectors for vaccine and immunotherapy applications |
| 04/24/2003 | CA2463991A1 Therapeutic composition and use |
| 04/24/2003 | CA2463729A1 Treatment of infectious disease using interleukin-1 beta converting enzyme (ice)/ced-3 family inhibitors |
| 04/24/2003 | CA2463676A1 Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans |
| 04/24/2003 | CA2463518A1 Carbinols for the treatment of neuropathic dysfunction |
| 04/24/2003 | CA2463469A1 4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes |
| 04/24/2003 | CA2462785A1 Kinases and phosphatases |
| 04/24/2003 | CA2462441A1 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors |
| 04/24/2003 | CA2462147A1 Bicyclic oxopyridine and oxopyrimidine derivatives |
| 04/24/2003 | CA2461740A1 Synthesis of cyclosporin analogs |
| 04/24/2003 | CA2461542A1 Gap junctions and endothelial-derived hyperpolarizing factor (edhf) |
| 04/24/2003 | CA2461245A1 Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders |